BioCentury | May 8, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: April 2019

New Therapeutic Targets and Biomarkers: April 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during April. Therapeutic targets are defined as any protein, gene or other molecule...
BioCentury | Apr 10, 2019
Distillery Therapeutics

UBR7 and CDH4 as targets for triple-negative breast cancer

DISEASE CATEGORY: Cancer INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest UBR7 or its downstream mediator CDH4 could help treat triple-negative breast cancer (TNBC). In tumor samples from patients with TNBC or...
BioCentury | Oct 19, 2018
Company News

Express Scripts adds Aimovig, Emgality to new value-based migraine program; excludes Ajovy

Express Scripts Holding Co. (NASDAQ:ESRX) will include two of three FDA approved migraine prevention drugs in its value-based program for migraine, which it unveiled Oct. 17. The PBM gave the nod to Aimovig erenumab-aooe from...
BioCentury | Oct 17, 2018
Company News

Express Scripts adds Aimovig, Emgality to new value-based migraine program; excludes Ajovy

Express Scripts Holding Co. (NASDAQ:ESRX) will include two of three FDA approved migraine prevention drugs in its value-based program for migraine, which it unveiled Wednesday. The PBM gave the nod to Aimovig erenumab-aooe from Amgen...
BioCentury | Dec 8, 2017
Targets & Mechanisms

Pathways emerging from ASH

A survey of the emerging molecular targets at this year’s American Society of Hematology conference indicates that while harnessing the immune system to treat cancer remains a dominant interest, processes for tuning protein levels --...
BioCentury | Dec 8, 2017
Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
BioCentury | Mar 31, 2017
Targets & Mechanisms

Cells on the rise

...n-recognin 1 (UBR1); UBR2; UBR5 Liver cancer Cell culture and mouse studies suggest inhibiting UBR1, UBR2...
BioCentury | Mar 30, 2017
Translation in Brief

An E3 for TNBC

With the multiple myeloma drug Velcade bortezomib having put E3 ubiquitin ligases on the drug development map, scientists are now taking aim at another E3 ligase for a hard-to-treat solid tumor: triple-negative breast cancer (TNBC)....
BioCentury | Mar 29, 2017
Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest inhibiting UBR5 could help treat triple-negative breast cancer (TNBC). In patient samples, high tumor expression of UBR5 correlated with disease progression. In a mouse...
BioCentury | Jan 7, 2016
Distillery Therapeutics

Therapeutics: Ubiquitin protein ligase E3 component n-recognin 4 (UBR4)

Infectious disease INDICATION: Influenza virus Cell culture and mouse studies suggest inhibiting UBR4 could help treat influenza A viral infection. Meta-analysis of eight published RNAi studies and three protein interaction data sets identified UBR4 as...
Items per page:
1 - 10 of 10